Moderna (NASDAQ:MRNA) Stock Rating Reaffirmed by Evercore ISI

Moderna (NASDAQ:MRNA)‘s stock had its “in-line” rating restated by equities researchers at Evercore ISI in a report issued on Thursday, Benzinga reports. They presently have a $120.00 target price on the stock. Evercore ISI’s price objective suggests a potential upside of 1.05% from the stock’s previous close.

A number of other brokerages have also recently issued reports on MRNA. William Blair restated a “market perform” rating on shares of Moderna in a report on Monday, April 1st. Needham & Company LLC restated a “hold” rating on shares of Moderna in a report on Monday, June 3rd. Canaccord Genuity Group lifted their target price on Moderna from $91.00 to $106.00 and gave the stock a “hold” rating in a report on Friday, May 3rd. Jefferies Financial Group restated a “buy” rating and issued a $125.00 target price on shares of Moderna in a report on Tuesday, April 9th. Finally, UBS Group raised their target price on Moderna from $143.00 to $151.00 and gave the stock a “buy” rating in a research report on Tuesday, May 7th. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $134.02.

Moderna Stock Down 2.0 %

Shares of MRNA stock opened at $118.75 on Thursday. Moderna has a 1 year low of $62.55 and a 1 year high of $170.47. The stock has a market cap of $45.51 billion, a PE ratio of -7.58 and a beta of 1.54. The business’s fifty day moving average is $134.13 and its 200-day moving average is $111.72. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.91 and a current ratio of 4.03.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings results on Thursday, May 2nd. The company reported ($3.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.59) by $0.52. The company had revenue of $167.00 million for the quarter, compared to analysts’ expectations of $93.26 million. Moderna had a negative return on equity of 20.10% and a negative net margin of 115.82%. The firm’s revenue for the quarter was down 91.0% on a year-over-year basis. During the same period last year, the firm earned $0.19 EPS. Equities analysts expect that Moderna will post -7.46 earnings per share for the current fiscal year.

Insider Activity at Moderna

In related news, Director Noubar Afeyan sold 202,832 shares of Moderna stock in a transaction on Tuesday, June 11th. The stock was sold at an average price of $148.34, for a total transaction of $30,088,098.88. Following the completion of the sale, the director now owns 1,528,557 shares of the company’s stock, valued at $226,746,145.38. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other Moderna news, President Stephen Hoge sold 15,000 shares of the firm’s stock in a transaction dated Monday, June 17th. The stock was sold at an average price of $138.16, for a total transaction of $2,072,400.00. Following the transaction, the president now directly owns 1,457,089 shares in the company, valued at $201,311,416.24. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Noubar Afeyan sold 202,832 shares of the firm’s stock in a transaction dated Tuesday, June 11th. The shares were sold at an average price of $148.34, for a total value of $30,088,098.88. Following the transaction, the director now owns 1,528,557 shares in the company, valued at $226,746,145.38. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 411,255 shares of company stock valued at $56,118,931. Insiders own 15.70% of the company’s stock.

Hedge Funds Weigh In On Moderna

Several institutional investors have recently bought and sold shares of MRNA. LPL Financial LLC raised its holdings in Moderna by 7.2% during the third quarter. LPL Financial LLC now owns 115,782 shares of the company’s stock valued at $11,959,000 after buying an additional 7,811 shares in the last quarter. Mariner LLC increased its stake in shares of Moderna by 5.2% in the third quarter. Mariner LLC now owns 20,242 shares of the company’s stock worth $2,091,000 after purchasing an additional 996 shares during the period. Stifel Financial Corp increased its stake in shares of Moderna by 19.0% in the third quarter. Stifel Financial Corp now owns 75,871 shares of the company’s stock worth $7,837,000 after purchasing an additional 12,099 shares during the period. Natixis Advisors L.P. increased its stake in shares of Moderna by 19.9% in the third quarter. Natixis Advisors L.P. now owns 19,924 shares of the company’s stock worth $2,058,000 after purchasing an additional 3,310 shares during the period. Finally, O Shaughnessy Asset Management LLC increased its stake in shares of Moderna by 34.0% in the third quarter. O Shaughnessy Asset Management LLC now owns 7,664 shares of the company’s stock worth $792,000 after purchasing an additional 1,945 shares during the period. 75.33% of the stock is currently owned by institutional investors.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.